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Abstract
Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) displays pleiotropic activities, both dependent and
independent of its inhibitory activity on matrix metalloproteinases (MMPs). In the central nervous system (CNS), TIMP-1 is
strongly upregulated in reactive astrocytes and cortical neurons following excitotoxic/inflammatory stimuli, but no
information exists on its effects on growth and morphology of cortical neurons.
Principal Findings: We found that 24 h incubation with recombinant TIMP-1 induced a 35% reduction in neurite length and
significantly increased growth cones size and the number of F-actin rich microprocesses. TIMP-1 mediated reduction in
neurite length affected both dendrites and axons after 48 h treatment. The effects on neurite length and morphology were
not elicited by a mutated form of TIMP-1 inactive against MMP-1, -2 and -3, and still inhibitory for MMP-9, but were
mimicked by a broad spectrum MMP inhibitor. MMP-9 was poorly expressed in developing cortical neurons, unlike MMP-2
which was present in growth cones and whose selective inhibition caused neurite length reductions similar to those
induced by TIMP-1. Moreover, TIMP-1 mediated changes in cytoskeleton reorganisation were not accompanied by
modifications in the expression levels of actin, bIII-tubulin, or microtubule assembly regulatory protein MAP2c. Transfection-
mediated overexpression of TIMP-1 dramatically reduced neuritic arbour extension in the absence of detectable levels of
released extracellular TIMP-1.
Conclusions: Altogether, TIMP-1 emerges as a modulator of neuronal outgrowth and morphology in a paracrine and
autrocrine manner through the inhibition, at least in part, of MMP-2 and not MMP-9. These findings may help us understand
the role of the MMP/TIMP system in post-lesion pre-scarring conditions.
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Introduction
TIMP-1 is the founding member of the MMP inhibitor family
encompassing four proteins with pleiotropic actions (TIMP-1-4).
In addition to inhibitory activity on proteinases hosted in the N-
terminal domain of the molecule, the TIMPs display MMP-
independent activities that regulate the behaviour of a wide range
of cell types [1]. The poorly known interactions with non
metalloproteinases involving the C-terminal domain of TIMPs
may contribute to their pleiotropic effects [2]. In the CNS, TIMP-
1 was first characterised as a candidate plasticity gene induced by
seizures and by stimuli leading to long term potentiation (LTP) [3],
a form of synaptic plasticity considered as a cellular substrate of
learning and memory. In developmental/physiological conditions,
TIMP-1 expression is very low and basically restricted to the
hippocampus and the cerebellum during the first postnatal weeks,
at a time of intense dendro-axonic remodelling [4,5]. In clear
contrast with physiological conditions, in the pathological brain
TIMP-1 expression is dramatically induced in a neuronal activity-
dependent manner in cortical and hippocampal neurons resistant
to excitotoxicity [4]. Despite prominent neuronal expression,
inflammation-driven TIMP-1 production by reactive astrocytes
prevails as the main source of the inhibitor in the pre-scarring
zones of lesion following seizures [4], cerebral ischemia [6],
experimental autoimmune encephalomyelitis [7], intracranial
injury [8], and viral infection [9]. Accordingly, TIMP-1 is
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transection and downregulated in nonscarring regenerating
conditions [10]. In vitro, proinflammatory cytokines such as
TNF-a or IL-1 upregulate TIMP-1 expression in astrocytes
[11,12] which stimulates astrocyte proliferation [13].
The upregulation of TIMP-1 in the pathological nervous
system is generally concomitant with the upregulation of some
of its main targets, MMP-9 and MMP-2 [14,15] and pinpoints
the importance of controled proteolytic balance in the
physiopathological outcome. In support of this idea, we have
recently demonstrated that, unlike wild type (WT) mice,
TIMP-1 deficient mice do not exhibit MMP-2 and MMP-9
upregulation after excitotoxic seizures, and this correlates with
the absence of mossy fibre sprouting in the hippocampus of
mutant mice [16]. The idea that these MMPs contribute to
neurite outgrowth in the CNS finds support in previous studies
implicating MMP-9 in neurite extension of cerebellar neurons
[ 1 7 ]a n di nr e c e n td a t ai n d i c a t i n gt h a tM M P - 3a n dM M P - 2
specifically promote axonal [18] and dendritic [19] growth in
cortical neurons, respectively. Moreover, MMP-2 has been
found to stimulate neurite outgrowth of dorsal root ganglia
(DRG) neurons in the peripheral nervous system [20].
Although these data suggest the involvement of TIMP-1 in
post-lesion structural changes of cortical and hippocampal
neurons [21,22], we still lack direct evidence that TIMP-1,
whether it is produced by neurons or by surrounding glial cells,
influences such changes. A way of addressing this question is to
investigate the impact of physiopathological concentrations of
TIMP-1 in neuronal morphology. We have combined a
systematic morphometric analysis of cultured cortical neurons
with the use of pseudophosphinic synthetic MMP inhibitors
[16,23], mouse recombinant full length TIMP-1, and recom-
binant WT and mutated inactive forms of the TIMP-1 N-
terminal domain [24] previously used to demonstrate the
determinant role of the N-terminal domain in the inhibition of
apoptosis in non neural cells [25]. Overall, TIMP-1 emerges as
a modulator of neuronal outgrowth and morphology through
paracrine and autrocrine actions and involves, at least in part
the inhibition of MMP-2 but not MMP-9. These findings may
be important to understand the role of the MMP/TIMP
system in post-lesion pre-scarring conditions.
Materials and Methods
Neuronal Cultures and Treatments
Primary cultures of cortical neurons were prepared from CD1
mice embryos according to the guidelines of the Ethics Committee
of the Medical Faculty of Marseilles and conform to National and
European regulations (EU directive Nu 86/609). Pregnant females
were deeply anesthetised with halothane (Nicholas Piramal
Limited, London, UK) and their placenta with embryos at
E17–18 were quickly removed and placed into cold HBSS
containing 0.5% glucose (both from Invitrogen, Carlsbad, CA,
USA). Usually, 4 embryos were used for each preparation. They
were decapitated and the cerebral cortices dissected, pooled and
enzymatically dissociated for 10 min at 37uC in HBSS containing
0.1% trypsine and 10 mg/ml DNase I (Sigma-Aldrich, Saint Louis,
MO, USA). The reaction was stopped by replacing the trypsin
medium with HBSS containing 10% foetal calf serum (Invitrogen).
Further mechanical dissociation was carried out in HBSS
containing 5 mg/ml of DNase by trituration through a Pasteur
pipette. After centrifugation at 1250 rpm during 5 min at room
temperature, the pelleted cells were resuspended in the plating
medium containing MEM, 0.6% glucose, 1 mM sodium pyruvate,
5 U/ml penicillin/streptomycin and 10% foetal calf serum (all
from Invitrogen). The cells were plated at a seeding density of 1.5
10
5 cells per well onto 12 mm diameter glass coverslips precoated
with 1 mg/ml poly-D-lysine (Sigma-Aldrich) in borate buffer
pH 8.5, and were grown at 37uC in a humidified chamber
containing 5% C02. After 90 min the plating medium was
aspirated and replaced by a serum free defined medium consisting
in Neurobasal, with 2% B27 supplement, 5 U/ml penicillin/
streptomycin, 2.5 mM glutamine (all from Invitrogen) and 25 mM
glutamate (Sigma-Aldrich). The following MMP inhibitors were
added to cultures in serum free media: mouse recombinant TIMP-
1 (mrTIMP-1, R&D System, Minneapolis, MN, USA) in (50 mM
Tris, 10 mM CaCl2, 150 mM NaCl, 0.05% Brij-35, pH 7.5)
(TCNB); human recombinant truncated N-terminal form of
TIMP-1 (NT1) with similar Ki values (0.2–0.4 nM) for MMP-1,
MMP-2, MMP-3 and MMP-9 and 146 nM for MT1-MMP; and
mutated inactive forms of TIMP-1 (DNT1), in which the
substitution of threonin in position 2 by glycine increases the Ki
value for MMP-1, MMP-2, MMP-3 and MT1-MMP by at least
two to three orders of magnitude [24]. DNT1 preserves a good
inhibitory activity for MMP-9 and exhibits a .2500-fold higher
affinity for MMP-9 relative to MMP-2 [26]; MMP selective
pseudophosphinic RXPO3R inhibitor that does not inhibit
adamalysins [23], with Ki for MMP-2, MMP-9 and MT1-MMP
of 55, 41 and 91 nM, respectively [27]; selective MMP-2 inhibitor
(MMP-2 inhibitor III, Calbiochem, La Jolla, CA, USA), which
exhibits good selectivity for MMP-2 (Ki 12 nM) when compared
with MMP-9 and MMP-3 (Ki 200 and 4500 nM, respectively).
Synthetic inhibitors were dissolved in DMSO 0.04% final
concentration. Controls were exposed to the same concentration
of DMSO.
Primary Astrocyte Cultures
Astrocytes were obtained from 2 days old CD1 mice brains as
described previously [28]. After removal of the meninges, the
brains were dissociated into a single-cell suspension by trypsinisa-
tion and mechanical disruption. The cells were seeded on onto
12 mm diameter glass coverslips and grown at 37uC in a 5% CO2
humidified atmosphere in Dulbecco’s modified Eagle medium
(DMEM) containing 10% foetal calf serum, 2 mM L-glutamine,
penicillin (100 U/ml), and streptomycin (100 mg/ml) (all from
Invitrogen). The medium was replaced every 3 days for 2 weeks
until reaching cell confluence and then replaced by a serum free
medium containing DMEM, L-glutamine, penicillin, and strepto-
mycin for 24 h.
Culture of Neuroblastoma Cells
Mouse neuroblastoma cells (N2a, also known as Neuro 2a,
ATCC, CCL-131
TM) were grown at 37uC in a humidified
atmosphere containing 5% CO2 in DMEM supplemented with
10% foetal bovine serum. Cells were grown to semi-confluence for
24 h before transfection (see below).
Reverse Transcription-Polymerase Chain Reaction (RT-
PCR)
Total RNA was isolated after lysis of cultured neurons, N2a cells
or astrocytes. Following OD assessment and gel analysis, 500 ng
total RNA was reverse transcribed. Traces of genomic DNA were
eliminated by a DNase I treatment for 15 min at 37uC. cDNAs
were used for amplification of TIMP-1, MMP-2, MMP-9, b-actin
and GAPDH, with the following cycling profile: 40 sec at 94uC,
40 sec at 58uC, 40 sec at 72uC for 28 to 35 cycles. The PCR
products were analysed in 2% ethidium bromide stained agarose
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different PCR products and their size in base pairs (bp) were as
follows:
Timp-1 F: GGCATCCTCTTGTTGCTATCACT,
Timp-1 R: CTTATGACCAGGTCCGAGTTGC (101 bp);
MMP-2 F: AGCGTGAAGTTTGGAAGCATC
MMP-2 R: GCTGGTTAACTACAGAGGAGGACAG (146
bp);
MMP-9 F: GACGACGACGAGTTGTGGTCGCT,
MMP-9 R: CGTCTGTGGTGCAGGCCGAATAG (130 bp);
MT1 F: AGAGCCAGGGTATCCCAAGT,
MT1 R: AACGCTGGCAGTAAAGCAGT (250 bp);
GAPDH F: TTGTCAAGCTCATTTCCTGGTATG,
GAPDH R: GGATAGGGCCTCTCTTGCTCA (143 bp);
b- Actin F: GGGACCTGACAGACTACCTCATG,
b-actin R: GAGGATGCGGCAGTGGC (161 bp).
Immunocytochemistry and Cytoskeleton Labelling
Cortical neurons or astrocytes were rinsed in phosphate buffer
saline (PBS) and fixed in 4% paraformaldehyde (PFA) for 10 min.
For immunocytochemistry, cells were pre-incubated with 0.1%
triton X-100, 3% bovine serum albumin (BSA, Sigma-Aldrich)
and 5% normal goat serum (NGS) (Jackson ImmunoResearch,
West Grove, PA, USA) for 60 min, followed by 90 min incubation
at room temperature with the following primary antibodies: mouse
anti-bIII-tubulin, (1/500, Sigma-Aldrich), rabbit anti-Glial Fibril-
lary Acidic Protein (GFAP) (1/400, Dako, Glostrup, Denmark),
mouse anti-phosphorylated Tau-1 (1/200, Sigma-Aldrich), chick-
en anti-MAP2 (1/10000, Abcam, Cambridge, UK) goat anti-
MMP-9 (1/100, R&D Systems) or goat anti-MMP-9 (1/100,
Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-
MMP-2 (1/200, Chemicon, Temecula, CA, USA), mouse anti-
Green Fluorescent Protein (GFP) (1/500, Roche Diagnostics,
Mannheim, Germany), and rabbit anti-ser3 p-cofilin (1/100,
Santa Cruz Biotecnology). Goat anti-TIMP-1 (1/100, R&D
Systems) was incubated overnight at 4uC. The antibodies were
diluted in PBS containing 0.1% triton X-100, 3% BSA, and 5%
NGS. The cells were then rinsed in PBS, incubated for 1 h with
Alexa FluorH 488–594, antibodies (1/600–800, Molecular Probes,
Eugene, OR, USA) or with biotinylated anti-goat antibody (1/
400, Jackson Immunoresearch) followed by 1 h additional
incubation with Alexa FluorH 488 streptavidin (1/400, Molecular
Probes) to reveal MMP-9 immunostaining, and 0.5 mg/ml of
nuclear marker Hoechst #33258 (Molecular Probes). For double
labelling experiments, the anti-bIII-tubulin and anti-GFAP
antibodies or the anti-Tau-1 and anti-MAP2 antibodies were
incubated together and the secondary antibodies used as indicated
above. For F-actin and nuclear labelling, cells were incubated after
immunocytochemistry with Texas Red-X phalloidin (Molecular
Probes), 0.5 mg/ml Hoechst #33258 in 0.1% triton, 3% BSA and
5% NGS for 1 h at room temperature, rinsed in PBS, and
mounted in fluorescence mounting medium (Dako). Cells were
observed under a Nikon E800 upright microscope equipped with
epifluorescence and TRITC, FITC and DAPI filters, and images
were analysed using an Orca-ER CCD camera (Hamamatsu
Photonics, Massy, France) and the LUCIA image analysis software
(Laboratory Imaging, Prague, Czech Republic).
Morphological Analyses
In each experiment, fluorescence microphotographs of at least 5
randomly selected fields per well and 3 wells per experimental
condition were taken, and the following parameters were analysed:
the total number of cells was determined on the basis of nuclear
Hoechst staining and ratios of bIII-tubulin or GFAP positive cells
determined from combined immunocytochemistry of neuronal or
glial markers. The neuronal processes and growth cones of all bIII-
tubulin positive cells were manually drawn using a computer
mouse. The mean length of the neuritic arbour was obtained by
dividing the total length of neurites in a field by the number of cells
immunoreactive for bIII-tubulin. At 48 h post-seeding, the same
procedure was used to determine the length of dendrites and axons
by measuring MAP2 and Tau-1 immunoreactive neurites,
respectively. The number of neurites per neuron was used as an
indication of branching and network complexity. A neurite
segment was defined as the distance between branching points
or the distance between the branching point and the tip of the
neurite. The mean number of neurite segments per neuron was
calculated from the number of segments per microscopic field
divided by the number of bIII-tubulin positive cells. The relative
frequency of neurites of a given length was classified by intervals of
10 mm. The number of growth cones per bIII-tubulin positive cell,
their shape, area and perimeter were analysed after fluorescence
labelling with Texas Red-X phalloidin. To test whether the shape
of growth cones was related to their dynamics, the index of
circularity or ‘‘f circle’’ (4 pi x area/perimeter crofton2) was
calculated. This parameter describes the degree to which a shape
differs from a circle and it varies from 0 to 1 (a perfect circle =1).
We analysed around 900 neurons per experiment.
Gel Zymography
Gel zymography was performed as previously described [6].
Culture supernatants were collected and protein concentrations
normalised using the Lowry method (Bio-Rad, Hercules, CA,
USA). Equal amounts of protein were subjected to 8.5% SDS-
PAGE (Bio-Rad) containing porcine gelatin at 4.5 mg/ml (Sigma-
Aldrich) in non-denaturing, non-reducing conditions and using a
MiniBlot system (Bio-Rad). Gels were washed twice for 30 min in
2.5% Triton X-100 to remove SDS, and incubated for 48 h in
50 mM Tris pH 7.5, 10 mM CaCl2,a t3 7 uC. Gels were then
stained with 0.1% Coomassie blue G-250 (Bio-Rad) for 3 h in
30% ethanol and destained with a solution containing 5% acetic
acid until clear bands of gelatinolysis appeared on a dark
background. Gels were digitised and optical densities assessed
with the Bio 1D software (Vilber Lourmat, Marne-la-Valle ´e,
France). Some zymogram gels were incubated with 1 mM 1,10-0-
phenanthrolin, a broad spectrum inhibitor of metalloproteinases.
Human recombinant active MMP-2 (hrMMP-2) (100–200 pg,
Chemicon) was used as a positive and normalising control.
Reverse Gel Zymography
Reverse gel zymography was performed according to the
method previously reported [29,30]. Culture supernatants and
lysates were collected and protein concentrations were normalised
as mentioned above. Equal amounts of protein were subjected to
8.5% SDS-PAGE containing 2.25 mg/ml porcine gelatin and
160 ng/ml of human recombinant active MMP-9 (Chemicon).
Samples were loaded in Laemmli buffer and run at constant
amperage (40 mA). The gels were incubated on a rotary shaker for
3 h in 2.5% Triton X-100. The Triton X-100 solution was
replaced with MMP activating buffer (50 mM Tris-HCl, pH 7.5,
10 mM CaCl2)a t3 7 uC for 48 h. Gels were then processed for
analysis as described above.
Isolation of Intracellular, Cytoskeletal and Membrane
Fractions
Subcellular fractioning was performed on cortical neurons using
the ProteoExtract subcellular proteome extraction kit (Calbio-
TIMP-1 and Neuron Morphology
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extracted with different buffers from major subcellular compart-
ments and on the basis of the difference in protein solubility. The
first cytosolic fraction was obtained by incubating the cells with an
extraction manufacturer’s buffer at 4uC for 10 min. A second
fraction contained the cell membrane and organelles, and
centrifugation of this fraction allowed separation of membrane
(supernatant) and cytoskeletal (pellet) fractions. Equal volumes of
each fraction samples were resolved by SDS-PAGE, and gel
zymography was performed as described above.
Extraction of Gelatinases and Western Blot
Culture supernatants from cortical neurons were collected 24 h
after seeding. For gelatinase extraction, supernatants were
concentrated using centrifugal filter devices (Amicon Ultra,
Millipore, Billerica, MA, USA) at 7500 x g during 15 min at
4uC, and were incubated in the presence of 60 ml of gelatin-
sepharose 4B (Amersham Biosciences, Buckinghamshire, UK)
overnight. Gelatin-sepharose 4B was eluted with working buffer
(50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM CaCl2, 0.005%
Brij-35) and 10% DMSO at room temperature. Protein
concentrations were determined using the Lowry method. Equal
amounts of protein in Laemmli buffer containing 10% b-
mercaptoethanol were boiled and separated by 8% SDS-PAGE.
mrTIMP-1 was loaded as positive control. Proteins were
transferred onto nitrocellulose membranes (Amersham Bioscienc-
es) in transfer buffer (25 mM Tris, 192 mM glycine, 20% ethanol).
Membranes were incubated overnight in blocking buffer at room
temperature and then probed with rabbit anti-MMP-2 (1/500,
Chemicon); goat anti-TIMP-1 (1/100, R&D Systems); mouse anti-
GFP (1/500, Roche Diagnostics); mouse anti-MAP2 (1/500),
mouse anti-bIII-tubulin (1/500) and mouse anti-b-actin (1/3000),
all three from Sigma-Aldrich; and rabbit anti-ser3 p-cofilin (1/500,
Santa Cruz Biotecnology). All antibodies were diluted in blocking
buffer (Roche Diagnostics). After incubation with primary
antibodies, membranes were incubated with a peroxidase
conjugated secondary antibody (Jackson Immunoresearch). Final-
ly, proteins were detected using a chemiluminescence kit (Roche
Diagnostics) and films were digitised and analysed using the Bio
1D software.
TIMP-1-GFP Construct and Transfections
Full length mouse TIMP-1 coding regions were amplified by
PCR from mouse brain cDNA produced as described above, using
the following primers containing unique restriction sites in their 39
end:
TIMP-1/GFP-F: ATATATGAATTCTAAATGATGGCCC-
CCTTTGCATCTCTG (EcoR1),
TIMP-1/GFP-R: ATATATGGATCCCGGGCCCCAAGG-
GATCTCCAAGT (BamH1).
The TIMP-1 PCR product was cloned in frame with GFP in
the EGFP (N1) vector (Clontech, Mountain View, CA, USA)
digested with the same enzymes beforehand and the plasmid
construct was fully sequenced on both strands.
Primary cortical neurons were seeded as indicated above. After
18–20 h in culture, the plating medium was aspirated and cells
were transfected using 1 mg of plasmid DNA encoding GFP or the
TIMP-1/GFP construct mixed with 5 ml of lipofectamine
(Invitrogen) and 1 ml of combimag beads (Magnetofection Kit
OZ Biosciences, Marseilles, France), according to the manufac-
turer’s protocol. The mix was incubated for 30 min on a magnetic
plate (OZ Bioscience) at 37uC and then replaced by pre-warmed
serum-free defined medium for 48 h until fixing in 4% PFA. N2a
cells were transfected using jetPEI (Qbiogene, Carlsbad CA, USA)
in Opti-MEM medium as recommended by the manufacturer.
Briefly, 1 mg of plasmid DNA encoding GFP or the TIMP-1/GFP
construct was mixed with 100 ml of NaCl 150 mM, 2 ml of jetPEI
and applied to 50000 cells plated on 12 mm diameter glass
coverslips 24 h after seeding. The supernatants of these cells were
collected 48 h after and used to assess the extent of TIMP-1/GFP
inhibition on MMPs. The transfection efficacy was .30%.
Fluorigenic Assay on mrTIMP-1 Inhibitory Activity
The inhibitory activity of mrTIMP-1 on active hrMMP-2 was
evaluated using a fluorimeter (DTX 800 Multimode Detectors,
Beckman Coulter, Fullerton, CA, USA). The cleavage of
gelatinase-specific quenched fluorescence substrate Mcmat
(0.5 mg) (Calbiochem), was measured as arbitrary fluorescence
units, using 325 nm excitation and 400 nm emission filters at 37uC
for 1 h. Twenty ng of active hrMMP-2 was used and the inhibitory
activity of 100 ng of mrTIMP-1 tested for 1 h. The control
contained 50 mM Tris/HCl, 10 mM CaCl2, 100 mM NaCl,
pH 6,8 (TCN buffer) and substrate, but no proteinase. A second
control was used to discard a possible inhibitory effect of the TNC
buffer in which mrTIMP-1 was diluted.
Statistical Analysis
Data were analysed using the analysis of the variance
(ANOVA), followed by either post-hoc Student-t, Tukey’s or
Dunnett’s test. Statistical significance was achieved at p#0.05.
Results
TIMP-1 Content in Cortical Neurons
Semi-quantitative RT-PCR was performed on mRNAs encod-
ing TIMP-1, MMP-2, MMP-9, MT1-MMP, GAPDH (Fig. 1A), b-
actin (not shown) and 18S RNA (not shown), the latter 3 being
used to standardise the experiments. PCR products were analysed
after 30 (not shown), 33 (not shown) and 35 cycles (Fig. 1A). While
TIMP-1, MMP-2, MT1-MMP and GAPDH PCR products were
already detected at 30 cycles, the MMP-9 PCR product was barely
detected even after 35 PCR cycles in cortical neurons cultured in
vitro for 24 h. At 39 cycles the MMP-9 PCR products was clearly
visible, but additional non specific products of weak intensity
appeared as well (not shown). The efficiency of the selected PCR
primers for MMP-9 was established by amplification of the
appropriate PCR product in N2a neuroblastoma cells (Fig. 1A)
and astrocytes (not shown). We thus conclude that in cortical
neurons cultured for 24 h MMP-9 mRNA is expressed at
significantly lower levels than the mRNAs encoding the other
proteins of interest in this study. Although TIMP-1 mRNA was
detected using RT-PCR approaches (Fig. 1A), the protein was
undetectable by western blot in the supernatants of our cultures
24 h after seeding (Fig. 1B) and immunolabelling was just slightly
above background levels in a few neurons (Fig. 1C). These data are
in agreement with previous reports showing low levels of TIMP-1
in physiological conditions [4,5]. In contrast with the low amounts
of TIMP-1 found in cortical neurons, the supernatant of control or
LPS-treated cortical astrocytes accumulated in 24 h between 10
and 100 ng/ml (,0.3–3 nM) of TIMP-1, as demonstrated by
western blot (not shown). Astrocytes also displayed intense
immunolabelling for TIMP-1 (not shown). Similar concentrations
of TIMP-1 have been reported in the cerebrospinal fluid of
patients suffering from various neurodegenerative disorders [31].
Together, these data determined the mrTIMP-1 working
concentrations in the present study and suggested that the low
levels of endogenous TIMP-1 would not interfere with exoge-
nously added mrTIMP-1. The latter was still easily detected by
TIMP-1 and Neuron Morphology
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indicating a good stability of the recombinant protein in culture
media conditioned by neurons (Fig. 1B). The MMP inhibitory
effect of mrTIMP-1 was confirmed by the inhibition of MMP-2
dependent cleavage of a fluorigenic substrate, as assessed by
spectrofluorescence (Fig. S1). Overall, the present experimental
model tentatively recreates the inflammatory/post-lesion situation
where most TIMP-1 is released into the neuronal microenviron-
ment by reactive astrocytes that express high levels of TIMP-1
compared to control, as previously reported [4,7].
Effects of mrTIMP-1 on Cell Culture Composition and
Viability
Twenty four hours after seeding, untreated cultures were
composed of 88.6% of bIII-tubulin positive cells with processes
(considered as differentiated neurons), 6.4% of bIII-tubulin
positive cells without neurite extensions (non-differentiated
neurons), 2.97% of GFAP positive cells and 2.03% of unidentified
cells negative for both neuronal and astrocytic markers (see
Table 1). Moreover, only a few neurons exhibited an incipient
axonal differentiation as assessed by double immunostaining with
anti-Tau-1 and anti-MAP2 antibodies, an axonal and a dendritic
specific marker, respectively. Virtually all neurons exhibited a
colocalised distribution of Tau-1 and MAP2 (Fig. S2) and only
11% of them displayed a slightly higher intensity of labelling for
Tau-1 in one of their neurites, which coexisted with conspicuous
MAP2 labelling. This clearly indicated a poor degree of axo-
dendritic differentiation at this stage in serum free pure neuronal
cultures, unlike cultures based on methods such as Banker’s, where
co-cultured astrocytes provide neurons with the necessary trophic
support for early axo-dendritic differentiation [32,33]. In contrast
with 24 h cultures, many neurons displayed a discrete distribution
of MAP2 and Tau-1 immunostaining at 48 and 72 h post-seeding
(Fig. 2D and Fig. S2, respectively), suggesting axo-dendritic
differentiation. Therefore, unbiased statistical evaluation of
mrTIMP-1 effects on the length of dendrites and axons was
possible at 48 h when the density of axo-dendritic circuitry
allowed for individual tracing of neurite extensions (Fig. 2D).
The number of cells in control cultures, counted as Hoechst
positive nuclei, remained constant across 10 independent exper-
Figure 1. Expression of TIMP-1 and MMPs in primary cortical neurons. A. Semi-quantitative RT-PCR followed by separation of the PCR
products in ethidium bromide stained gels showing expression by cortical neurons 24 h after seeding and by N2a neuroblastoma cells of mRNAs
encoding endogenous TIMP-1, MMP-2, MMP-9 and MT1-MMP after 35 cycles of PCR. Note that in cortical neurons, MMP-9 mRNA is barely detected as
compared with N2a cells and with the other neuronal mRNAs which were already detected at 30 cycles of PCR. GAPDH (30 cycles) was used as a
standard; 100 bp molecular weight ladder (M). B. Western blot showing TIMP-1 immunoreactivity after equal protein loading from supernatants of
cortical neurons at different times after adding 2.5 nM of mrTIMP-1, or from control untreated cultures at the same time points, 0, 24 and 72 h. Note
that endogenous TIMP-1 is not detected in untreated cultures, whereas mrTIMP-1 is easily detected in the supernatants of these cultures even after
72 h, indicating high stability of the protein. C. Fluorescent microphotographs of cortical neurons showing bIII-tubulin (green) and TIMP-1 (red)
immunostaining co-labelled with the nuclear marker Hoechst (blue) 24 h after seeding. Note low levels of endogenous TIMP-1, slightly above
background levels (Blank) only in the soma of some cells. Scale bar 20 mm. Figures are representative of at least 3 independent experiments.
doi:10.1371/journal.pone.0008289.g001
Table 1. Effects of mrTIMP-1 on the content of cortical
cultures 24 h after seeding.
mrTIMP-1 (nM) 0 0.4 1 2.5
# Hoechst positive cells 6064.8 6366.7 6465.8 6263.3
% astrocytes 2.960.2 n.a. 6.260.4* 3.560.4
% differentiated neurons 8960.7 8562.2 8661.2 8761.1
% non differentiated neurons 6.460.7 8.562.2 7.161.2 6.760,9
mrTIMP-1 induced no changes in the number of viable cells or in the number of
differentiated or non differentiated neurons. However, it augmented the
number of GFAP positive cells. Values represent the means 6 SEM of 4–8
independent experiments * p,0.01, ANOVA followed by Dunnett’s test.
doi:10.1371/journal.pone.0008289.t001
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2). This
number of viable cells was not affected by 24 h exposure to
mrTIMP-1 at any concentration studied and the treatment did not
induce any sign of cytotoxicity such as chromatin compaction or
neurite breakage, and did not alter the ratio of differentiated and
non-differentiated bIII-tubulin positive cells (Table 1).
Twenty four hours following exposure to 1 nM mrTIMP-1, the
number of astrocytes doubled (Table 1) as compared with
untreated control cultures. Although these experiments were not
set up to study the effects of TIMP-1 on astrocytes, which
represent a very low percentage of cells, the present results are in
keeping with previous observations in primary cultures of cortical
astrocytes, where TIMP-1 increased [
3H] thymidine uptake by
200% [13].
Effects of mrTIMP-1 on Neurite Length in Cortical
Neurons
Previous work in our laboratory suggested the implication of
TIMP-1 in the control of axonal remodelling in vivo [16] and
prompted us to investigate more specifically the effects of
mrTIMP-1 on cultured neurons. Twenty four hours of exposure
to mrTIMP-1 was considered as a minimum time for TIMP-1 to
act in neurons after pathological driven upregulation. The length
of neurites, measured in bIII-tubulin labelled cells, was signifi-
Figure 2. Effects of mrTIMP-1 on neurite outgrowth of cortical neurons 24 and 48 h after seeding. A. Fluorescent microphotographs of
cortical neurons showing bIII-tubulin staining 24 h after seeding. Note that the length of neurites decreases after exposure to mrTIMP-1 (1 nM in the
example). B. Quantification of these reductions after 24 h exposure to several concentrations of mrTIMP-1. C. Quantification by intervals of length,
indicating that mrTIMP-1 induces an important increase in the proportion of small neurites (between 0 and 10 mm), whereas longer neurites are
significantly more frequent in the control cultures. D. Fluorescent microphotographs of cortical neurons showing immunostaining for Tau-1 (green)
and MAP2 (red), and Hoechst labelling (blue) 48 h after seeding. The graph represents the length of axons (a), dendrites (d) and the total neuritic
arbour (a+d). Note that 48 h of treatment with mrTIMP-1 significantly reduced the size of both axons and dendrites. Values represent the means 6
SEM of 3–8 independent experiments. *p,0.05, **p,0.01, ANOVA followed by Dunnett’s (graph B) and Student-t (graphs C and D) tests. Scale bars
20 mm.
doi:10.1371/journal.pone.0008289.g002
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(Fig. 2A and B). In addition, as illustrated in figure 2C for the
1 nM concentration, the majority of the smallest neurites [0;
10 mm] were observed in cultures treated with mrTIMP-1. This
proportion was similar between control and mrTIMP-1-treated
cultures in the next length interval [10; 20 mm] and was inverted
in the [20; 30 mm] interval and thereafter, with control cultures
displaying a higher number of the longer neurites. In addition, the
longest neurites were systematically found in control cultures. The
effects of mrTIMP-1 on the distribution of length frequencies were
similar regardless of the concentration studied: 0.4 nM (n=4),
1 nM (n=4), 2.5 nM (n=8). The inhibitory effects of mrTIMP-1
on neurite outgrowth were still present after 48 h treatment and
affected equally both dendrites and axons (Fig. 2D)
Effects of mrTIMP-1 on Actin Cytoskeleton and Growth
Cone Morphology
To assess changes in the morphology of growth cones and other
actin rich structures, we stained F-actin using Texas Red-X
phalloidin. Microscopic observation revealed that cultures exposed
to mrTIMP-1 for 24 h exhibited a less organised actin network
and an increased number of actin rich filopodia along the neurite
shaft (Fig. 3A). Indeed, the number of these protrusions nearly
doubled as compared to control cultures (Fig. 3B). Moreover, the
area of leading growth cones augmented almost 2-fold (Fig. 3C)
after exposure to mrTIMP-1. No significant changes were
observed in the index of circularity (not shown).
mrTIMP-1 Did Not Alter the Levels of Cytoskeletal
Proteins
We next sought to examine whether morphological changes
would be supported by changes in the levels of cytoskeletal
proteins such as b-actin, b-III-tubulin, or MAP2c, a regulator of
microtubule assembly. Using western blot approaches, no changes
were observed in their expression levels after 24 h treatment,
suggesting that mrTIMP-1 effects on cortical neuron morphology
rather result from redistribution of cytoskeletal components
(Fig. 3D). In order to further ascertain a possible link between
TIMP-1 effects and a signalling cascade in relation with actin
polymerisation and depolymerisation, we sought for changes in the
phosphorylation of cofilin, an actin binding protein that
depolymerises actin and looses this capacity upon phosphoryla-
tion. Using an anti-ser 3 p-cofilin antibody, previously reported to
allow for detection of subtle changes in cofilin phosphorylation
[34], we could not detect significant modifications in the levels of
phosphocofilin after mrTIMP-1 treatment either by western blot
(Fig. 3E) or by immunofluorescence (results not shown).
Effects of Wild Type and Mutated Inactive Forms of
Truncated N-Terminal TIMP-1 on Cortical Neurons
Both the N-terminal and C-terminal domains of TIMP-1
influence its biological functions. The N-terminal domain
interacts with the active site of the target MMP and carries the
MMP inhibitory activity, whereas the C-terminal domain
conveys the binding to pro-MMP-9 and protein-protein
interactions that confer to TIMP-1 functions independent of
MMP inhibition [2]. In order to distinguish between these two
possibilities, we investigated the effects on cortical neuronal
cultures of wild type (NT1) and mutated (DNT1) truncated N-
terminal forms of TIMP-1 after 24 h exposure. The NT1 form
of the protein preserves the MMP inhibitory activity of full
length TIMP-1 against MMP-1, MMP-2, MMP-3 and MMP-9
and a relatively poor inhibitory activity against MT1-MMP.
These inhibitory capacities are completely abrogated in the
DNT1 mutated form with the exception of MMP-9 inhibition
which is selectively preserved [35,26]. In the presence of
2.5 nM NT1, neurite length was significantly reduced by 32%,
whereas the DNT1 mutated form did not induce significant
changes with respect to the control group (Fig. 4A). These
observations clearly indicate that TIMP-1 effects on the
morphology of cortical neurons are predominantly mediated
by the inhibition of MMP activity.
Effects of Broad Spectrum Specific MMP Inhibitor
In order to confirm that the MMP inhibitory properties of the
N-terminal domain of TIMP-1 modulate neuronal morphology,
we next asked whether broad spectrum MMP inhibitors would
mimic TIMP-1 effects. We used RXPO3R (2 mM), a pseudopho-
sphinic MMP inhibitor which does not inhibit the closely related
ADAM family of metalloproteinases [23,16]. Like the full length
mrTIMP-1 and its NT1 variant, 24 h of exposure to RXPO3R
significantly reduced the length of neurites and increased the area
of growth cones (Fig. 4B and C), without affecting cell viability or
the proportion of differentiated neurons (not shown). The
convergence of the effects induced by TIMP-1, NT1 and
RXPO3R on the morphology of cortical neurons further supports
the idea that TIMP-1 effects are mainly mediated by its inhibitory
activity on MMPs.
Effects of a TIMP-1/GFP Fusion Protein Expressed in
Cortical Neurons
The data above demonstrate that exogenous mrTIMP-1
affects neuron morphology and hence recreate a paracrine
action of TIMP-1 when released, for instance, by reactive
surrounding glia in different pathological settings. However,
inflammation driven expression of TIMP-1 by glia is normally
preceded by the induction of TIMP-1 expression in cortical
and hippocampal neurons resistant to degeneration [4,6].
Therefore, we next asked whether TIMP-1 also elicits
autocrine effects on neuron outgrowth. To address this
question, we generated a plasmid construct encoding a mouse
TIMP-1/GFP fusion protein that retains the inhibitory activity
of TIMP-1 on MMPs, as demonstrated by reverse zymography
on supernatants from N2a transfected cells (Fig. 5A). Forty
eight hours after transfection the transgene was homogeneous-
ly distributed in all cell compartments of both bIII-tubulin
positive (Fig. 5B) and negative cells (not shown). The first
represented 2.02% of total cells in the culture, whereas bIII-
tubulin negative cells (presumably astrocytes) accounted for
0.5%. These percentages reached 2.06% and 16.6% when the
number of TIMP-1/GFP transfected cells was respectively
referred to the number of neuronal or non-neuronal cells,
clearly indicating a higher transfection rate for the latter.
Western blot (Fig. S3) using anti-GFP antibody did not reveal a
detectable presence of TIMP-1/GFP in the supernatants of
transfected cultures. In these conditions, as illustrated in
figures 5C and 5D, TIMP-1/GFP overexpression strongly
reduced neurite length (48.3%) and the number of neurites
(51.8%). We also attempted to evaluate the effects of TIMP-1/
GFP overexpression on actin cytoskeleton, but after nearly
70 h in culture transfected cells were not longer individualised
and their extensions and growth cones were intermingled with
surrounding neurons (Fig. S4). The few transfected and
isolated neurons found in each experiment (only 3–4 per well
for each experimental group) were not sufficient to reveal
significant changes on the size of growth cones after TIMP-1/
GFP overexpression.
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PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8289Figure 3. Effects of mrTIMP-1 on the morphology of cortical neurons and expression of cytoskeletal proteins. A. Fluorescent
microphotographs of cultured cortical neurons labelled with Texas Red-X phalloidin, showing increases in the size of growth cones (arrowheads) and
the number of F-actin rich filopodia (arrows) after 24 h of mrTIMP-1 treatment (1 nM) as compared with control cultures. B and C. Quantification of
these changes showing significant increases in the number of filopodia/mm of neurite (B), and the area of growth cones (C) after mrTIMP-1
treatment. D. Western blot from lysates of cortical neurons treated with 1 nM mrTIMP-1 for 24 h showing no differences between control (C) and
mrTIMP-1 treated (T) cultures for different cytoskeleton proteins (MAP2c, b-actin and bIII-tubulin). E. Western blot and quantification of phospho-
cofilin levels from lysates of cortical neurons (3 independent experiments). No changes were observed after treatment with 1 nM mrTIMP-1 for 24 h.
b-actin was used as a control of equal protein loading. Images in A, B and D are representative of results obtained in 4 independent experiments.
Values in B and C represent the means 6 SEM of 4 independent experiments. *p,0.05, ** p,0.01, Student-t-test (B); Dunnett’s test (C). Scale
bar 20 mm.
doi:10.1371/journal.pone.0008289.g003
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9, and Effects of MMP-2 Selective Inhibition
Since RXPO3R and TIMP-1 are very poor inhibitors of
ADAMs and MT-MMPs, respectively, it is plausible that their
effects on neuron growth and morphology result from the
inhibition of secreted MMPs synthesised by cortical neurons.
Gelatinases MMP-2 and MMP-9 are potential targets for TIMP-1.
The MMP-2 mRNA was clearly more abundant than MMP-9
mRNA and this ratio was preserved at the protein level. Indeed,
MMP-2 gelatinolytic activity (,70 kDa) was consistently displayed
in the supernatant, cytosolic and membrane fractions of cultured
neurons. MMP-9 gelatinolytic activity (,100 kDa) was relatively
faint in the supernatant and occasionally detected in the cytosol.
Both proteinases were detected in the membrane fraction, which
displayed a more conspicuous band of lower molecular weight, as
compared with the supernatant and cytosolic fractions (Fig. 6A).
Considering that MMP-9 has a 5-fold higher gelatinolytic capacity
than MMP-2, we found that the latter was between 6-fold and 24-
fold more abundant than MMP-9 in the tested fractions (Fig. 6B).
The expression of MMP-2 by cortical neurons was further
confirmed by western blot (Fig. 6C) and immunocytochemistry
(Fig. 6D). The levels of MMP-9 were not sufficient to be
unequivocally detected with two different antibodies by western
blot or immunocytochemistry in any of the experiments we
performed (not shown). In contrast, MMP-2 immunolabelling
appeared to be punctate in the cell body and neurites and often
conspicuous in the growth cone (Fig. 6D). MMP-2 immunoreac-
tivity was mainly observed in the central domain of the growth
cone and generally excluded from the more motile peripheral
domain rich in F-actin (Fig. 6D). Provided that MMP-2 was
constitutively expressed by cortical neurons and in particular in
areas that are essential for neurite outgrowth, we tested whether
the latter was affected by selective inhibition of MMP-2. The
range of concentrations of MMP-2i used was calculated to provide
a level of MMP-2 inhibition comparable with that provided by
TIMP-1 on the basis of their Ki. As illustrated in figure 7, the
selective MMP-2i reduced neurite length after 24 h of exposure in
a dose-dependent manner with a significant inhibitory effect (25%)
detected at 100 nM, and a maximum effect (35%) at 1000 nM.
The same concentrations of MMP-2i did not induce any changes
in the surface of growth cones or in the number of actin rich
protrusions (not shown).
Discussion
The present work provides evidence that TIMP-1 modulates the
morphology of neurons in a paracrine and autocrine manner. The
paracrine actions of TIMP-1 appear to be mediated by its N-
terminal domain which carries the inhibitory activity on MMPs,
most likely on MMP-2. This proteinase, constitutively expressed
by cortical neurons, is present in the cell soma, the neurites and the
central domain of growth cones. Its inhibition by a selective MMP-
2 inhibitor causes neurite length reductions comparable with those
induced by TIMP-1, the latter equally affecting both dendrites and
axons. The autocrine action of overexpressed TIMP-1/GFP
causes an even more important reduction in neurite length and
branching. Altogether, TIMP-1 emerges as a factor that modulates
the size and number of actin rich structures (growth cones and
microprocesses) and neurite outgrowth by inducing a reorganisa-
tion of the actin and tubulin cytoskeleton. Our findings may be of
functional relevance mainly in post-lesion pre-scarring zones of the
CNS where TIMP-1 is released at high levels by reactive
astrocytes and by hyperactive neurons.
Figure 4. Inhibition of neurite outgrowth by the N-terminal
domain of TIMP-1. A. Plot representing the average length of
neurites per neuron after 24 h treatment with 2.5 nM of mrTIMP-1, the
wild type form of the N-terminal domain of TIMP-1 (N-TIMP-1) or the
mutated inactive form of the latter (DN-TIMP-1). B and C. Plots
representing the effects of RXPO3R (2 mM) on the length of neurites (B)
and the area of the growth cone (C). The values represent the means 6
SEM of at least 3 independent experiments. *p,0.05, ANOVA followed
by Tukey’s (A) or Student-t (B and C) test.
doi:10.1371/journal.pone.0008289.g004
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Cones and F-Actin Rich Microprocesses
High expression of TIMP-1 in reactive astrocytes compared
with much lower neuronal levels has been documented by
different groups including ours [4]. In the present study only 3%
of cells were identified as astrocytes by GFAP labelling, suggesting
a minor contribution of these glial cells to TIMP-1 and MMP
content. Although RT-PCR revealed the presence of TIMP-1
mRNA in cortical neurons, the protein was undetectable by
western blot, in clear contrast with easily detected TIMP-1 (0.3–
3 nM) in the supernatant of quiescent and LPS-stimulated
astrocytes found in the present study (not shown) or in the
cerebrospinal fluid of patients with neurodegenerative disorders
[31]. The pathological concentrations of TIMP-1 in body fluids
are within the range of those used in the present study that
induced changes in the growth and morphology of neurons. The
reduction of neurite length was concomitant with the increase in
the number of small bIII-positive neurites (under 10 mm) and actin
rich protrusions. These are highly dynamic structures that expand
and retract constantly and it is possible that TIMP-1 stabilises
them through an increase in their adhesion to extracellular
substrates. An alternative, but non exclusive hypothesis is that
TIMP-1 could act as a repellent cue for growth cones,
subsequently leading to the emergence of lateral protrusions.
Similar effects have been previously reported for repellent cues
that inhibit growth cone motility of retinal ganglion cells [36],
suggesting that secondary neurites emerging from the protrusions
might compensate the sensory deficit of the leading growth cone.
Although an increase in the size of growth cones is most commonly
associated with expanding neurites, the 2-fold increase of the
growth cone size observed upon TIMP-1 application is on the
contrary concomitant with the reduction of neurite outgrowth. No
clear explanation exists for such phenomenon, but it has been
suggested that changes in microtubule dynamics may slow down
neuritic outgrowth and facilitate the accumulation of material
within the growth cone [37]. The question remains open as to
whether TIMP-1 induces a transient collapse of growth cones in a
way reminiscent of classical collapsing-like factors (ie, ephrin,
semaphorins, etc). Investigating the kinetics of TIMP-1 action
should provide further insight into the activation of signalling
pathways preceding significant morphological changes. In this
context, failure to detect changes in cofilin phosphorylation at
24 h after seeding does not preclude that such changes may
actually occur at earlier time points.
TIMP-1 Induced Changes in Neuronal Morphology Are
Mediated by Its N-Terminal Domain
The finding that RXPO3R, a specific inhibitor of MMPs,
essentially mimicked the effects of TIMP-1 provides indirect
evidence that TIMP-1 targeting of MMPs is a causal event. Recent
reports have suggested the implication of ADAMs in axon
outgrowth and guiding in DRG and retinal ganglion cells [38].
The effects of the RXPO3R, which does not inhibit ADAMs [23],
argues against a significant implication of these metalloproteinases
Figure 5. Effects of TIMP-1/GFP fusion protein on the morphology and neurite development of cortical neurons. A. Reverse gel
zymography from supernatants of N2a cells transfected with TIMP-1/GFP fusion protein demonstrating that TIMP-1/GFP retains inhibitory activity on
MMP proteolytic activity. Note that the band of inhibited MMP-9 activity corresponds to the size of TIMP-1 (33 kDa) + GFP (28 kDa). B. Examples of
cortical neurons transfected with GFP or TIMP-1/GFP and immunostained with an anti-GFP antibody 48 h after transfection. White fluorescence
photomicrographs were converted to black negative images to improve the details on the neuritic arbour. Note that TIMP-1 overexpression in these
neurons strongly reduces the complexity of their arborisation. Scale bar 20 mm. C and D. Quantification of the changes induced by TIMP-1/GFP
overexpression compared to GFP alone. The values represent the means 6 SEM of 4 independent experiments. *p,0.05, Student-t-test.
doi:10.1371/journal.pone.0008289.g005
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contingency would apply to MT-MMPs provided the poor
inhibitory effect of TIMP-1 on the members of this MMP
subfamily.
The most compelling evidence for a MMP inhibition-dependent
action of TIMP-1 comes from data demonstrating that the
truncated wild type N-terminal form of TIMP-1 reduces neurite
outgrowth, whereas the inactive mutated form does not. Our data
confirm in live cortical neurons previous studies showing that the
truncated TIMP-1 retains metalloproteinase inhibitory activity in a
cell-free system [39]. Altogether, these findings pinpoint the
functional prevalence of the primary amino-acid sequence in the
inhibitory properties of the N-terminal domain over post transla-
tional modifications such as glycosylation, not present in the
truncatedform produced by bacteria. From the above it follows that
the C-terminal domain of TIMP-1 may be irrelevant in the
molecular processes leading to the inhibition of neurite outgrowth.
TIMP-1 Effects on Neurite Outgrowth of Cortical Neurons
Appear Mediated in Part by the Inhibition of MMP-2
MMP-9 has been reported to contribute to axonal elonga-
tion in cerebellar neurons [17] but two findings in our study
suggest that this proteinase does not play a critical role in
neurite extension of cortical neurons; first, MMP-9 levels are
Figure 6. Expression of MMP-2 and MMP-9 in cortical neurons 24 h after seeding. A. Gelatin zymograms of MMP-2 and MMP-9 from
supernatant of cortical neurons, cytosol and membrane fractions. Human active recombinant MMP-2 (hrMMP-2) was used as a positive control
(200 pg). The zymogram shows much higher expression of MMP-2 (,70 kDa) than MMP-9 (,100 kDa) in the supernatant, higher expression of MMP-
2 in the cytosol where MMP-9 is barely detectable, and rather similar intensity of gelatinolytic bands for both gelatinases in the membrane fraction. B.
Quantification of the MMP-2/MMP-9 ratio from zymograms, where active recombinant MMP-2 was used as normalising control. Values represent the
means 6 SEM of 3 independent experiments. Note that the quantification takes into consideration a 5-fold higher gelatinolytic activity of MMP-9
than MMP-2. C. Western blot demonstrating MMP-2 immunoreactivity in the supernatants of cortical neurons after enrichment and precipitation of
the samples with gelatin beads. Active human recombinant MMP-2 (5 ng) was used as a positive control. Images are representative of 3 independent
experiments. D. Fluorescence microphotographs showing immunolabelling of MMP-2 (green) and phalloidin F-actin labelling (red) in cortical neurons
24 h after seeding. Hoechst #33258 stained the nuclei (blue). Note that MMP-2 is distributed in the cell body and neurites. In the growth cones,
MMP-2 is mainly located to the central domain (insets with high power magnifications in the lower row) and virtually excluded from F-actin rich areas,
notably the peripheral domain. Scale bars are 20 mm for entire neurons and 10 mm for close up of growth cones.
doi:10.1371/journal.pone.0008289.g006
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terminal mutated form of TIMP-1 that selectively preserves
MMP-9 inhibition had no effect on neurite outgrowth.
Therefore, it is reasonable to conclude that the inhibitory
effects of TIMP-1 on neurite outgrowth are not mediated by
the inhibition of MMP-9. Instead, several lines of evidence
p o i n tt oM M P - 2a st h em o s tp l a u s i b l et a r g e to fT I M P - 1i n
cortical neurons. Indeed, unlike MMP-9, MMP-2 was consti-
tutively expressed and particularly concentrated in the central
domain of the growth cone, known to be enriched in
microtubules [40,41]. The exclusion of MMP-2 from areas
rich in F-actin (ie, filopodia) suggests a possible functional
connection of MMP-2 with the microtubular system, known to
act as the principal structural component of neurite extension
and retraction. In support of this hypothesis, we have recently
shown that in neuronal cells, MMP-2-containing vesicles are
transported along microtubules, in close interaction with the
kinesin molecular motors [30]. The possibility that the effects
of TIMP-1 result from the inhibition of MMP-2 finds further
support in the observation that a synthetic selective MMP-2
inhibitor also reduces neurite length. Our findings, whether
referred to the 24 or 48 h time-point reinforce recent data
suggesting the involvement of MMP-2 in dendrite outgrowth of
cortical neurons [19]. The same authors previously suggested
that MMP-3 rather contributes to axonal growth [18]. In this
context, we cannot exclude that the effects of mrTIMP-1 on
axons, observed at 48 h, involve the inhibition of MMP-3.
The absence of MMP-2 from growth cone areas enriched in F-
actin (ie, peripheral domain of the growth cone) is in line with the
failure of selective MMP-2i to affect the size of growth cones or the
number of actin rich microfilaments. These data suggest that
TIMP-1 effects on actin rich structures involve the inhibition of
another MMP likely to be inhibited by the broad spectrum MMP
inhibitor RXPO3, which did increase the surface of growth cones.
Altogether, these observations support a role for at least a TIMP-
1/MMP-2 interaction in the control of neurite outgrowth in
cortical neurons. This is in keeping with the role previously
attributed to MMP-2 in the motility of DRG [20] and
hippocampal [16] neurons, and astrocytes [42]. Our data also
open the way to the investigation of TIMP-1 interactions that
specifically support changes in the dynamics of the actin
cytoskeleton.
Overexpression of TIMP-1 in Cortical Neurons Reduces
Neurite Outgrowth in an Autocrine Way
The important reduction of the neuritic arbour caused by
transfected TIMP-1/GFP compared to GFP alone confirms that
TIMP-1 interferes with normal outgrowth of cortical neurons
regardless of its locus of synthesis. It is noteworthy that
overexpression of TIMP-1/GFP causes a stronger reduction in
neurite outgrowth than exogenous mrTIMP-1. These exacerbated
effects may result from higher local concentrations of TIMP-1/
GFP in and around the transfected neurons that inhibit MMP-2
more efficiently, but may also reflect the effects of the interactions
of TIMP-1/GFP with other intracellular and pericellular targets
that would be less available for the exogenously applied mrTIMP-
1. Little is known about the interactions of TIMP-1 with non-
metalloproteinase proteins. Recently, it has been suggested that in
epithelial cells TIMP-1 interacts with the surface protein CD63
and modulates the tetraspanin/integrin b1 signaling complex [43].
Such interactions have not yet been reported for TIMP-1 in
neurons, but the closely related TIMP-2 has been found to interact
with a3b1 integrin in cultured cortical neurons and to promote
neurite outgrowth and differentiation of PC12 cells through cell-
cycle arrest [44]. Moreover, TIMP-3 promotes neuronal apoptosis
by blocking the shedding of the tumour necrosis factor (TNF)
superfamily of death receptors/ligands by MMP-3 [45,46].
Overall, it appears that the different TIMPs have clearly distinct
or even opposite effects in the nervous system, thus influencing cell
survival and neurite outgrowth balance in developmental and/or
post-lesion processes. Although the present study is focused on the
effects of TIMP-1 on cultured primary neurons, our data may
provide with clues to understand the functional consequences of
TIMP-1 production in post-lesion or inflammatory pre-scarring
zones of the CNS, but also to investigate the implication of TIMP-
1 in learning processes [16,47] and LTP [48] on the basis of its
ability to shape neuronal and synaptic morphology. These
challenging questions will deserve further attention in the future
to ascertain the role of TIMP-1, and more generally of the MMP/
TIMP system, in the CNS at the crossroads of physiology and
pathology.
Supporting Information
Figure S1 Inhibitory effect of mrTIMP on hrMMP-2 proteolytic
activity. Fluorescence generated by cleavage of the fluorescein
quenched substrate (Mcmat, 0.5 mg) is expressed as arbitrary
fluorescence units (AFU). Mcmat cleavage by human recombinant
MMP-2 (hr MMP-2, 20 ng) was inhibited by mouse recombinant
TIMP-1 (mrTIMP-1, 100 ng) diluted in TCNB (Tris, CaCl2,
NaCl, Brij-35 0.05%), reaching values equivalent to those
representing the control (buffer and Mcmat, without proteinase).
Note that the TCNB has no inhibitory effect on hrMMP-2
proteolytic activity.
Found at: doi:10.1371/journal.pone.0008289.s001 (0.46 MB TIF)
Figure S2 Absence of axo-dendritic differentiation in cortical
neurons 24 h after seeding. Fluorescent microphotographs show-
ing immunolabelling for Tau-1 (green) and MAP2 (red) specific
markers of axons and dendrites, respectively. Hoechst #33258
stained the nuclei (blue). At 24 h post-seeding, tau expression is
low and essentially colocalised with MAP2, indicating no axonal
differentiation at this stage. To the contrary, at 72 h post-seeding,
specific labelling is shown for MAP2 in dendrites (arrowheads) and
Tau-1 in axons (arrows). Scale bar 20 mm.
Figure 7. Selective MMP-2 inhibition reduces neurite length.
Plot representing the average length of neurites per neuron after 24 h
treatment with a selective MMP-2 inhibitor. The reduction of neurite
length is dose-dependent. The values represent the means 6 SEM of 4
independent experiments. *p,0.05, Dunnett’s test.
doi:10.1371/journal.pone.0008289.g007
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Figure S3 TIMP-1/GFP is not detected in the supernatant of
transfected cortical neurons. Western blot from supernatants (S)
and lysates (L) of N2a cells and neurons 24 or 48 h after
transfection with TIMP-1/GFP constructs. The transgene is
detected in N2a cells, where transfection rates are over 30%,
whereas it is not detected in transfected neuronal cultures that
yielded much lower transfection rates. Note that the molecular
weight of the secreted transgene corresponds to the size of the
fusion protein ,60 kDa, while the lysates exhibit also a truncated
form of the protein at ,43 kDa. The western blot is representative
of 3 independent experiments.
Found at: doi:10.1371/journal.pone.0008289.s003 (0.33 MB TIF)
Figure S4 TIMP-1/GFP transfection and actin cytoskeleton
labelling. Fluorescent microphtographs showing anti-GFP immu-
nostaining (green) and F-actin phallodin labelling (red). Hoechst
#33258 stained the nuclei (blue). Note that transfected neurons
appear well integrated in the neuronal circuitry and most neurites
and growth cones are intermingled with neuritic extensions from
non-transfected neurons. Scale bars 20 mm.
Found at: doi:10.1371/journal.pone.0008289.s004 (3.81 MB TIF)
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